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Abstract
Coronaviruses cause disease in animals and people around the world. Human coronaviruses (HCoV) 
are mainly known to cause infections of the upper and lower respiratory tract but the symptoms may 
also involve the nervous and digestive systems. Since the beginning of December 2019, there has been an 
epidemic of SARS-CoV-2, which was originally referred to as 2019-nCoV. The most common symptoms 
are fever and cough, fatigue, sputum production, dyspnea, myalgia, arthralgia or sore throat, headache, 
nausea, vomiting or diarrhea (30%). The best prevention is to avoid exposure. In addition, contact per-
sons should be subjected to mandatory quarantine. COVID-19 patients should be treated in specialist 
centers. A significant number of patients with pneumonia require passive oxygen therapy. Non-invasive 
ventilation and high-flow nasal oxygen therapy can be applied in mild and moderate non-hypercapnia 
cases. A lung-saving ventilation strategy must be implemented in acute respiratory distress syndrome 
and mechanically ventilated patients. Extracorporeal membrane oxygenation is a highly specialized 
method, available only in selected centers and not applicable to a significant number of cases. Specific 
pharmacological treatment for COVID-19 is not currently available. Modern medicine is gearing up 
to fight the new coronavirus pandemic. The key is a holistic approach to the patient including, primar-
ily, the use of personal protective equipment to reduce the risk of further virus transmission, as well as 
patient management, which consists in both quarantine and, in the absence of specific pharmacological 
therapy, symptomatic treatment. (Cardiol J 2020; 27, 2: xx–xx)
Key words: coronavirus, COVID-19, SARS-CoV-2, pandemic, symptoms, epidemiology, 
healthcare, treatment, medical stuff
Introduction
Since the beginning of December 2019, there 
has been an epidemic of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), which was 
originally referred to as 2019-nCoV. The first cases 
of infection and the subsequent development of the 
disease named COVID-19 were identified in the city 
of Wuhan, in the Chinese province of Hubei. On March 
11, 2020, the World Health Organization (WHO) 
declared SARS-CoV-2 pandemic. The virus has now 
spread almost worldwide and as of March 31, 2020, 
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there have been 862,234 confirmed infection cases 
and 42,404 deaths.
The information on the coronavirus is updated 
daily. Currently, the epicenter is already outside 
China, in the United States of America (USA), Italy 
and Spain, where 189,633 and 105,792 and 95,923 
cases, respectively, were confirmed as of March 
31, 2020. The number of COVID-19 deaths in Italy 
has far exceeded the number of deaths recorded 
in China. Now it equals 8165 cases, while in China 
3169 cases were reported. The new epicenter in 
the USA is prognosed with an increasing number 
of new cases emerging daily.
The aim of this article was to describe the 
taxonomy and pathogenicity of coronaviruses, 
including SARS-CoV-2, and to present recom-
mendations for the diagnosis and management of 
patients with COVID-19.
Epidemic versus pandemic
An epidemic can be identified when a disease 
occurs at a certain time and in a certain area, and 
there are more cases than expected. A pandemic 
has a global scope: it involves several continents. 
Historically, one can point to several epidemics, in-
cluding the plague of 1347–1351, which killed over 
25 million people. The most recent recurrence of 
the plague took place between 1855 and 1859, when 
it was called the “third great plague pandemic” [1]. 
Smallpox, on the other hand, between 1520 and 
1979, killed 56 million people. However, one of 
the deadliest epidemics was Spanish influenza, 
which killed over 50 million people between 1918 
and 1920. During the epidemic, several waves of 
the disease were recorded. At first, it was highly 
contagious, but mild in its course; however, the 
second wave of the flu began in August and was 
characterized by extremely high mortality, mainly 
because of the additional occurrence of bronchial 
pneumonia [2]. The third phase took place in the 
winter of 1918/1919. A characteristic feature of the 
last two phases of the so-called Spanish influenza 
was a high mortality rate among 20–40-year-olds, 
which is unusual for “normal” seasonal influenza, 
which takes its lethal toll mainly on the youngest 
children and seniors. Other epidemics include the 
Asian influenza (1957–1958), which caused be-
tween 1 and 2 million deaths [3], the Hong Kong 
influenza (1968–1970), with 1–4 million deaths 
[4], the swine influenza (2009–2010), with 284,500 
deaths [5], and the Ebola epidemic (2013–2016), 
with 11,300 deaths [6].
History of coronavirus-related diseases
Coronaviruses belong to the Coronoviridae 
family, classified in recent years in the order of 
Nidovirales [7]. Depending on the serotype and 
genotype, coronaviruses are divided into four 
genera, designated as a, b, g, and d [8], with hu-
man coronaviruses (HCoV) belonging to the first 
two [9].
Coronaviruses cause disease in animals and 
people around the world. HCoV is mainly known 
to cause infections of the upper and lower respira-
tory tract but the symptoms may also involve the 
nervous and digestive systems [10]. Of all the 
coronaviruses that threaten humans, 5 were de-
scribed in the 21st century. These are: HCoV-NL63, 
HCoV-HKU1, HCoV-SARS, HCoV-MERS and 
SARS-CoV-2. The first coronaviruses reported — 
in 1966 and 1967, respectively — were HCoV-229E 
and HCoV-OC43, both presented with cold symp-
toms. Initially, only these two coronaviruses were 
considered to be dangerous for patients. In 2003, 
a breakthrough occurred, and HCoV-SARS virus 
was identified. Both HCoV-SARS and HCoV-MERS 
are zoonotic viruses, causing human infection from 
animals. It is assumed that bats are their natural 
reservoir (Fig. 1) [11].
In the case of zoonotic viruses, the interspe-
cies barrier between bats and other mammals has 
been broken and, as a result of the fixation of the 
virus’s transmission in these animal groups, the 
animals have become an intermediate link. The 
only other element was the transmission of the 
infection to humans. It can therefore be concluded 
that the interspecies barrier was broken down at 
least twice to make such pathogens as HCoV-SARS 
and HCoV-MERS dangerous to humans.
HCoV-SARS virus was responsible for more 
than 8000 cases in people between 2002 and 2003, 
mainly in Asia, and was the etiological agent of 
severe acute respiratory syndrome (SARS). At that 
time, over 700 cases ended in the death of those 
people. In the transmission chain of the HCoV-
SARS virus infection, Asian palm civet played a ma-
jor role, which is considered a delicacy in Chinese 
cuisine. Another indirect host for HCoV-SARS was 
the Asian yenote [12, 13]. The HCoV-SARS virus 
is transmitted by the droplet pathway, through a 
close contact with an infected person. The trans-
mission in aerosol form in ventilation systems of 
buildings has also been confirmed. The virus enters 
the lungs, where it directly damages alveoli cells 
causing acute respiratory failure. The incubation 
Figure 1. Animal origin of human coronaviruses.
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period for symptoms of SARS virus infection is 3–7 
days [14]. The initial phase of the disease does not 
present specifically; flu-like symptoms dominate: 
fever with chills, fatigue, headaches, muscle pain, 
malaise, lack of appetite, while nausea, vomiting, 
rhinitis, coughing, or dizziness are less frequent. 
These symptoms may persist for 3–7 days, followed 
by rapid decompensation of the patient as a result 
of inflammation of the lower airways, manifested by 
dry cough, dyspnea, and respiratory failure. Mortal-
ity as a result of HCoV-SARS is estimated at 7%.
For the HCoV-MERS virus, causing Middle 
East respiratory syndrome (MERS) — an acute 
infectious disease — camels are the indirect 
host. Seroepidemic studies have shown that the 
HCoV-MERS-like virus has been causing camel 
infections and diseases for years, especially in the 
Arabian Peninsula and Africa. Human infection can 
also occur through contact with excretions of an 
infected camel (from the respiratory tract, urine, 
feces, etc.), as well as during the processing of 
camel meat and other products.
The disease is characterized by fever above 
38 degrees Celsius, cough, and other respira-
tory symptoms, such as shortness of breath and 
dyspnea; moreover, pneumonia, acute respiratory 
failure, septic shock, or multi-organ failure may 
develop. Gastrointestinal symptoms (diarrhea) are 
sometimes observed. Death occurs in over 36% 
of patients. The hatching period ranges from 2 to 
14 days. There is no vaccine for MERS and the 
treatment is symptomatic [14, 15]. Because of a 
high resistance of coronaviruses to environmental 
conditions and the ability to maintain infectivity in 
the form of aerosol, it is believed that the disease 
is most likely to occur in the droplet pathway.
SARS-CoV-2 and COVID-19:  
Epidemiology, pathology, and symptoms
The first case of SARS-CoV-2 infection in the 
form of acute respiratory failure was reported on 
December 12, 2019 in the city of Wuhan in the 
central-eastern province of China, Hubei. The 
symptomatology resembled that of SARS [16]. Sci-
entists immediately started to investigate the new 
coronavirus, and the first genome of COVID-19 was 
published by a research team led by Prof. Zhang on 
January 10, 2020 [17]. The SARS-CoV-2 genotype 
resembles that of viruses causing SARS (45–90%) 
and MERS (20–60%). The name of the virus refers 
to the fact that it causes airway infections similar 
to SARS. However, SARS-CoV-2 presents the 
greatest genetic similarity, of nearly 89%, to the 
coronavirus genome found in bats [18]. This may 
indicate that bats were the first host. On the other 
hand, Lorusso et al. [19] observed 99% identical 
coronavirus strains in Chinese civets. Subsequent 
cases in which SARS and MERS were excluded 
were reported on December 31, 2019, while the 
determination of the infection causative factor was 
made public 9 days later [20]. Due to the onset of 
the pandemic in China, most scientific publications 
on the virus currently refer to Chinese patients. 
As is the case of SARS and MERS, the primary 
route of spreading COVID-19 is a droplet pathway. 
Figure 2. COVID-19 symptoms.
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It is worth remembering that HCoV-SARS, HCoV-
MERS, and SARS-CoV-2 can also be transmitted 
via environmental vectors. Wang et al. [21] indi-
cated that the time from the onset of the disease 
to death was shorter in people over 70 years of 
age compared to younger patients (11.5 and 20 
days, respectively). Yang et al. [22] indicated that 
in COVID-19-infected patients, comorbidities and 
the diagnosed underlying diseases, including hy-
pertension, respiratory system and cardiovascular 
diseases, which may be risk factors for severe when 
compared with a non-severe course of the disease.
The complete clinical manifestation is not 
clear yet, as the reported symptoms range from 
mild to severe, with some cases resulting in death. 
Guan et al. [23] have shown that the most com-
mon symptoms are fever (in 88.7% of patients), 
cough (67.8%), fatigue (38.1%), sputum production 
(33.7%), shortness of breath (18.7%), myalgia or 
arthralgia (14.9%), or sore throat (13.9%). In ad-
dition, symptoms from the nervous and digestive 
systems should also be considered. Liu et al. [24] 
also indicate headache (53.3%) as an important 
symptom of the disease, as well as nausea, vomit-
ing, or diarrhea (30%). Figure 2 shows both typical 
and less frequent symptoms of COVID-19. In many, 
the infection remains asymptomatic. Li et al. [25] 
implied that patients with mild symptoms were re-
ported to recover after 1 week while severe cases 
experienced progressive respiratory failure due to 
alveolar damage from the immunological response 
to the virus, which may lead to death. Severely af-
fected patients are referred to intensive care units 
because of acute pneumonia, sepsis, septic shock, 
or acute respiratory distress syndrome.
The hatching period for COVID-19 lasts 2–14 
days, but current studies indicate that it can be as 
long as 21 days [18, 26]. The virus is highly infec-
tious, as confirmed by recent epidemiological data. 
As of March 26, 2020, the reported number of con-
firmed infection cases equaled 510,108. COVID-19 
mortality is 4.5% and turns out to be lower than 
that in SARS or MERS, but the disease dynamics 
are very high. 
COVID-19 suspicion procedure
The best prevention is to avoid virus ex-
posure. In addition, contact persons should be 
subjected to mandatory quarantine. However, this 
is not possible for medical personnel, who should 
therefore be equipped with specialized personal 
protective equipment. Airborne precautions and 
other protective measures have been discussed 
and proposed for prevention [27]. Proper use 
and disposal of masks is important to avoid any 
increase in risk of transmission [28, 29]. Infection 
preventive and control measures that may reduce 
the risk of exposure include the following: use of 
face masks; covering coughs and sneezes with 
tissues that are then safely disposed of; regular 
hand washing with soap or disinfection with hand 
sanitizer containing at least 60% alcohol; avoidance 
of contact with infected people and maintaining an 
appropriate distance; and refraining from touch-
ing eyes, nose, and mouth with unwashed hands. 
Figure 3. Paramedic dressed in antibiological protection equipment.
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While the infected persons should wear masks to 
reduce the risk of infecting other people, medical 
personnel should be equipped with particulate 
respirators such as the certified N95 or FFP2 when 
performing aerosol-generating procedures and 
use of medical masks while providing any care to 
suspected or confirmed cases [30]. In accordance 
with WHO guidelines on the use of masks in the 
community, during home care and in health care 
settings in the context of the novel coronavirus 
2019-nCoV [29], persons with respiratory symp-
toms should wear medical masks in health care 
and home care settings, properly following the 
infection prevention guidelines. The individuals 
without respiratory symptoms are not required to 
wear medical masks when in public, although this 
statement is questioned by an increasing number 
of experts. Medical personnel, including paramed-
ics, in addition to protective masks of N95 or FFP2 
type, should also be equipped with antibiological 
protection, including specialized overalls, gloves, 
glasses, or visors (Fig. 3).
When a SARS-CoV-2 infection is suspected, 
emergency teams as well as medical dispatchers 
should apply specific algorithms of management. 
An example is presented in Figure 4. The manage-
ment can be divided into two main paths, depending 
on the patient’s condition. If symptoms of upper 
respiratory tract infection are observed without 
dyspnea and with temperatures below 38 degrees 
Celsius, the patient should be directed to an isola-
tion site and await test result. If the patient’s con-
dition deteriorates, a dedicated ambulance should 
transport them to an infectious department or 
dedicated infectious hospital. These departments 
or hospitals should also be chosen for patients 
with dyspnea, cough, and temperatures above 38 
degrees Celsius, including those in severe condi-
tions with coexisting diseases requiring intensive 
medical monitoring.
Transporting a patient with a suspicion of 
COVID-19 should always be performed by a dedi-
cated emergency team. However, in many situa-
tions, the emergency medical service staff perform 
interventions where they may suspect a coronavi-
rus infection only on the basis of an examination 
and interview. Then, after transport, the ambulance 
should be disinfected with disinfectants with a wide 
range of viricidal effects [26].
Diagnosis
The main step in the diagnosis of SARS-CoV-2 
infection is positive epidemiological history. Deng 
and Peng [31] indicate that risk factors should be 
divided into two groups: epidemiological (group A) 
and clinical ones (group B). If any group A factor 
occurs, once at least two group B symptoms are 
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present, the infection should be suspected. Epi-
demiological factors include: traveling to or living 
in an area where the disease occurs; contact with 
a patient who has a confirmed infection; contact 
with a patient with fever and respiratory symp-
toms from an area where the infection occurs; 
occurrence of the disease in the group/family. 
Clinical factors are the following: fever and/or 
respiratory symptoms; pneumonia with radiologi-
cal symptoms; normal or reduced white blood cell 
count or reduced lymphocyte count in the early 
stages of the disease. However, first stage cases 
may be asymptomatic, with no fever. A confirmed 
case is a suspected case with a positive molecular 
test. Specific diagnosis is performed by specific 
molecular tests with respiratory samples (throat 
swab, nasopharyngeal swab, sputum, endotracheal 
aspirate, bronchoalveolar lavage). The virus may 
also be detected in the stool and, in severe cases, 
blood. It must be remembered that the multiplex 
polymerase chain reaction (PCR) panels currently 
available do not include COVID-19.
All patients with severe COVID-19 should be 
screened for hyperinflammation by using labora-
tory trends. Lymphopenia and leukopenia are char-
acteristic of COVID-19 in its initial stage; however, 
as indicated by Lippi and Plebani [32], about 30% 
of patients treated in China were found to have 
increased leukocyte values. In infected patients, 
increased myoglobin levels, as well as increased 
creatine kinase, aminotransferases (ALT and AST) 
and lactate dehydrogenase activity are also found. 
C-reactive protein concentration presents elevated 
values in these patients with normal procalci-
tonin levels. With severe infection, an increase in 
creatinine, D-dimers, and lactate levels can also 
be observed [33]. A cytokine profile resembling 
secondary hemophagocytic lymphohistiocytosis is 
associated with COVID-19 severity, characterized 
by increased interleukin MCP1, MIP1a, IL-2, IL-7, 
IL-10, GSCF, IP10, or TNF-a [34, 35].
In the case of SARS-CoV-2 infection, because 
of the affinity of the virus to the airways, it is 
important to perform a chest X-ray. Computed to-
mography scanning provides an important basis for 
early diagnosis and treatment of novel coronavirus 
pneumonia. In the course of COVID-19, one can 
expect changes characteristic of severe respira-
tory tract infections similar to those in SARS. In 
the initial stage of infection, interstitial lesions and 
patchy ground glass opacities in the peripheral areas 
under the pleura dominate the radiological picture. 
In the next phase, these areas are rounded off and 
infiltrating changes appear. However, among severe 
patients, characteristic consolidation changes with-
out pleural effusion can be observed [36].
For patients with suspected infection, the fol-
lowing diagnostic procedures have been suggested: 
Figure 4. Algorithm for dealing with suspected SARS-CoV-2 infection.
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performing real-time fluorescence (RT-PCR) to 
detect the positive nucleic acid of SARS-CoV-2 in 
sputum, throat swabs, and secretions of the lower 
respiratory tract samples [37]. 
Treatment
COVID-19 patients should be treated in spe-
cialist centers. The current trend is to create 
unified infectious hospitals in which patients with 
confirmed SARS-CoV-2 infection are treated. 
A significant number of patients with pneumonia 
require passive oxygen therapy. In the first phase 
of oxygen therapy, a flow of 5 L/min is applied and 
then gradually titrated to obtain an oxygen concen-
tration of ≥ 90% SpO2 for adults and children and 
92–95% SpO2 for pregnant women. As indicated by 
Huang et al. [35], 5% of patients requiring invasive 
mechanical ventilation. These are mainly patients 
with acute respiratory distress syndrome and hy-
poxemic respiratory failure.
Non-invasive ventilation and high-flow na-
sal oxygen therapy can be applied in mild and 
moderate non-hypercapnia cases, but the patient 
should be assessed for respiratory failure. Li [38] 
suggests that if there is no improvement within 
1 hour despite high-flow nasal oxygen, endotra-
cheal intubation and mechanical lung ventilation 
should be used. A lung-saving ventilation strategy 
must be applied. The respiratory rate should be 
as low as possible and the tidal volume should not 
exceed 6 mL for predicted body weight to maintain 
a pH greater than 7.2. During mechanical venti-
lation, positive end-expiratory pressure should 
also be used. For the most critically ill patients, 
extracorporeal membrane oxygenation is an op-
tion [39]. However, it should be stressed that this 
is a highly specialized method, available only in 
selected centers and not applicable to a significant 
number of cases.
Specific pharmacological treatment for COVID-19 
is not currently available. Many centers use em-
pirical antiviral treatment with lopinavir/ritonavir, 
remdesivir, ribavirin, nelfinavir, umifenovir, favip-
iravir, or other derivatives, among others [40, 41]. 
Camostat mesylate, licensed in pancreatitis and 
reflux esophagitis in Japan is postulated to inhibit 
a human protein involved with infection — it is 
a commercially available inhibitor of the enzyme 
transmembrane protease, serine 2 (TMPRSS2) 
[42]. Anti-malaria drugs are postulated. Among 
them, chloroquine is registered as the drug for mild 
stages of COVID-19 in few countries [43], off label 
use of its derivative — hydroxychloroquine is ad-
vised by some groups of experts [44]. Therapeutic 
options also include steroids, intravenous immu-
noglobulin, selective cytokine blockade (e.g. anak-
inra or tocilizumab), and Janus kinase inhibition 
(baricitinib) [45]. Antibiotics should not be applied 
without microbiological confirmation of bacterial 
infection, with an exception of chloroquine/hydrox-
ychloroquine combined with azithromycin as an 
experimental way to reduce the viral load [46, 47]. 
In cases of infection with a bacterial background, 
broad-spectrum antibiotics are recommended. In 
septic shock, glucocorticosteroids should be admin-
istered, e.g. hydrocortisone at an intravenous dose 
of 50 mg repeated every 6 hours, which is, however, 
subject to discussion. In patients with circulatory 
failure, norepinephrine should be applied to maintain 
organ perfusion while reducing fluid supply. The first 
non-blinded partially randomized trial organized by 
the WHO — SOLIDARITY trial — which compares 
4 types of treatment: remdesivir vs. chloroquine/hy-
droxychloroquine vs. lopinavir/ritonavir vs. lopinavir/
ritonavir plus interferon-beta were launched on March, 
20th, 2020. WHO’s website will randomize patients to 
local standard care or one of the four drug regimens, 
using the only ones available at the patient’s hospital. 
Some simple outcomes, which are easy to collect 
and report will be gathered: the day the patient left 
hospital or died, the duration of hospital stay, require-
ments of oxygen or ventilation [48, 49]. It might 
reveal some real evidence for COVID-19 treatment 
until new methods, vaccines, convalescent plasma 
products, specific monoclonal antibodies directed at 
SARS-CoV-2 or a sudden stop of pandemic is awaited.
Summary
Modern medicine, including emergency medi-
cine, is geared to fighting the new coronavirus. 
Since the appearance of the first cases in Decem-
ber 2019, SARS-CoV-2 has been the cause of the 
pandemic. The key is a holistic approach to the 
patient, primarily including the use of personal 
protective equipment to reduce the risk of further 
virus transmission, as well as patient management, 
which consists in both quarantine and, in the ab-
sence of proved specific pharmacological therapy, 
symptomatic treatment.
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